Opus Genetics, Inc.
IRD
$4.04
-$0.02-0.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -50.64% | -10.16% | -20.38% | 159.17% | 155.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.64% | -10.16% | -20.38% | 159.17% | 155.41% |
| Cost of Revenue | 33.41% | 48.25% | -28.65% | -1.05% | 65.68% |
| Gross Profit | -138.87% | -140.23% | 34.90% | 36.87% | -14.99% |
| SG&A Expenses | -6.24% | -32.99% | 72.11% | 71.91% | 37.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.54% | 6.89% | -4.09% | 24.87% | 51.81% |
| Operating Income | -44.67% | -14.20% | -3.77% | -6.94% | -28.81% |
| Income Before Tax | -699.79% | 52.97% | -131.92% | 4.44% | -15.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -699.79% | 52.97% | -131.92% | 4.44% | -15.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -699.79% | 52.97% | -131.92% | 4.44% | -15.31% |
| EBIT | -44.67% | -14.20% | -3.77% | -6.94% | -28.81% |
| EBITDA | -44.73% | -14.10% | -3.63% | -6.79% | -28.67% |
| EPS Basic | -211.91% | 82.29% | 14.17% | 61.06% | 16.56% |
| Normalized Basic EPS | -211.98% | 12.80% | 14.17% | 61.04% | 16.47% |
| EPS Diluted | -211.91% | 82.29% | 14.17% | 61.06% | 16.56% |
| Normalized Diluted EPS | -211.98% | 12.80% | 14.17% | 61.04% | 16.47% |
| Average Basic Shares Outstanding | 156.43% | 165.44% | 170.17% | 145.39% | 38.19% |
| Average Diluted Shares Outstanding | 156.43% | 165.44% | 170.17% | 145.39% | 38.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |